Streptococcal Vaccines: Current Status and Future Directions

Dear Colleagues,

We are pleased to invite you to submit an article to this Special Issue titled “Streptococcal Vaccines: Current Status and Future Directions”.  The submission deadline is 31 July 2026.

Streptococcal infections are among the most common bacterial infections. Among Streptococcal species, three are of significant concern: (a) Group B Streptococcus (GBS), causing serious infections like pneumonia, sepsis, and meningitis; (b) Streptococcus pneumoniae, causing a common community-acquired pneumonia, particularly in young children and the elderly; and (c) Group A Streptococcus (GAS), causing strep throat, skin and bloodstream infections, and deadly rheumatic heart diseases. Vaccines against S. pneumoniae are available (e.g., Prevenar 13, Pneumovax 23); however, they do not offer universal protection, while vaccines against other streptococci are in development. Given the global spread, growing antibiotic resistance, and high mortality rate related to systemic infections and autoimmune postinfection complications, the need for the development of vaccines against these bacteria is of high priority.

In this Special Issue, original research articles and reviews are welcome and may include the following topics:

1. Vaccine development against Group A or B Streptococcus;
2. Vaccines targeting other Streptococcal species;
3. Adjuvants in streptococcal vaccines;
4. Animal models for streptococcal vaccines;
5. Clinical trials on the Streptococcal vaccines.

We look forward to receiving your contributions.

Dr. Mariusz Skwarczynski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.